Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Impact of extracellular vesicles on innate immunity.

Chen Z, Larregina AT, Morelli AE.

Curr Opin Organ Transplant. 2019 Dec;24(6):670-678. doi: 10.1097/MOT.0000000000000701.

PMID:
31592838
2.

Oral administration of lipoteichoic acid from Lactobacillus rhamnosus GG overcomes UVB-induced immunosuppression and impairs skin tumor growth in mice.

Friedrich AD, Campo VE, Cela EM, Morelli AE, Shufesky WJ, Tckacheva OA, Leoni J, Paz ML, Larregina AT, González Maglio DH.

Eur J Immunol. 2019 Nov;49(11):2095-2102. doi: 10.1002/eji.201848024. Epub 2019 Jul 31.

PMID:
31334839
3.

Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis.

Li G, Larregina AT, Domsic RT, Stolz DB, Medsger TA Jr, Lafyatis R, Fuschiotti P.

J Invest Dermatol. 2017 May;137(5):1042-1050. doi: 10.1016/j.jid.2016.11.037. Epub 2016 Dec 22.

4.

Donor dendritic cell-derived exosomes promote allograft-targeting immune response.

Liu Q, Rojas-Canales DM, Divito SJ, Shufesky WJ, Stolz DB, Erdos G, Sullivan ML, Gibson GA, Watkins SC, Larregina AT, Morelli AE.

J Clin Invest. 2016 Aug 1;126(8):2805-20. doi: 10.1172/JCI84577. Epub 2016 Jun 27.

5.

Concise Review: Mechanisms Behind Apoptotic Cell-Based Therapies Against Transplant Rejection and Graft versus Host Disease.

Morelli AE, Larregina AT.

Stem Cells. 2016 May;34(5):1142-50. doi: 10.1002/stem.2326. Epub 2016 Feb 29. Review.

6.

Clinical implications of basic science discoveries: nociceptive neurons as targets to control immunity--potential relevance for transplantation.

Larregina AT, Divito SJ, Morelli AE.

Am J Transplant. 2015 Jun;15(6):1472-4. doi: 10.1111/ajt.13158. Epub 2015 Apr 6. Review.

7.

Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses.

Sumpter TL, Ho CH, Pleet AR, Tkacheva OA, Shufesky WJ, Rojas-Canales DM, Morelli AE, Larregina AT.

J Allergy Clin Immunol. 2015 Apr;135(4):1019-30.e8. doi: 10.1016/j.jaci.2014.07.036. Epub 2014 Sep 4.

8.

Methods of purification of CTL-derived exosomes.

Montecalvo A, Larregina AT, Morelli AE.

Methods Mol Biol. 2014;1186:87-102. doi: 10.1007/978-1-4939-1158-5_7.

PMID:
25149305
9.

Methods of analysis of dendritic cell-derived exosome-shuttle microRNA and its horizontal propagation between dendritic cells.

Montecalvo A, Larregina AT, Morelli AE.

Methods Mol Biol. 2013;1024:19-40. doi: 10.1007/978-1-62703-453-1_3.

PMID:
23719940
10.

Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12.

Janelsins BM, Sumpter TL, Tkacheva OA, Rojas-Canales DM, Erdos G, Mathers AR, Shufesky WJ, Storkus WJ, Falo LD Jr, Morelli AE, Larregina AT.

Blood. 2013 Apr 11;121(15):2923-33. doi: 10.1182/blood-2012-07-446054. Epub 2013 Jan 30.

11.

Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation.

Keyel PA, Tkacheva OA, Larregina AT, Salter RD.

J Immunol. 2012 Nov 1;189(9):4621-9. doi: 10.4049/jimmunol.1200828. Epub 2012 Sep 26.

12.

Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis.

Fuschiotti P, Larregina AT, Ho J, Feghali-Bostwick C, Medsger TA Jr.

Arthritis Rheum. 2013 Jan;65(1):236-46. doi: 10.1002/art.37706.

13.

Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant.

Ferris LK, Mburu YK, Mathers AR, Fluharty ER, Larregina AT, Ferris RL, Falo LD Jr.

J Invest Dermatol. 2013 Feb;133(2):460-8. doi: 10.1038/jid.2012.319. Epub 2012 Sep 6.

14.

Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis.

Ruiz XD, Mlakar LR, Yamaguchi Y, Su Y, Larregina AT, Pilewski JM, Feghali-Bostwick CA.

PLoS One. 2012;7(8):e43049. doi: 10.1371/journal.pone.0043049. Epub 2012 Aug 10.

15.

A peptide derived from endostatin ameliorates organ fibrosis.

Yamaguchi Y, Takihara T, Chambers RA, Veraldi KL, Larregina AT, Feghali-Bostwick CA.

Sci Transl Med. 2012 May 30;4(136):136ra71. doi: 10.1126/scitranslmed.3003421.

16.

Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs.

Wang Z, Divito SJ, Shufesky WJ, Sumpter T, Wang H, Tkacheva OA, Wang W, Liu C, Larregina AT, Morelli AE.

Am J Transplant. 2012 Jun;12(6):1398-408. doi: 10.1111/j.1600-6143.2012.04060.x. Epub 2012 Apr 14.

17.

Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes.

Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Milosevic J, Tkacheva OA, Divito SJ, Jordan R, Lyons-Weiler J, Watkins SC, Morelli AE.

Blood. 2012 Jan 19;119(3):756-66. doi: 10.1182/blood-2011-02-338004. Epub 2011 Oct 26.

18.

Role of neurokinin-1 receptor in the initiation and maintenance of skin chronic inflammatory diseases.

Divito SJ, Morelli AE, Larregina AT.

Immunol Res. 2011 Aug;50(2-3):195-201. doi: 10.1007/s12026-011-8219-9.

PMID:
21717076
19.

Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation.

Divito SJ, Wang Z, Shufesky WJ, Liu Q, Tkacheva OA, Montecalvo A, Erdos G, Larregina AT, Morelli AE.

Blood. 2010 Oct 14;116(15):2694-705. doi: 10.1182/blood-2009-10-251058. Epub 2010 Jun 24.

20.

Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells.

Morelli AE, Larregina AT.

Apoptosis. 2010 Sep;15(9):1083-97. doi: 10.1007/s10495-010-0469-9. Review.

21.

In situ-targeting of dendritic cells with donor-derived apoptotic cells restrains indirect allorecognition and ameliorates allograft vasculopathy.

Wang Z, Shufesky WJ, Montecalvo A, Divito SJ, Larregina AT, Morelli AE.

PLoS One. 2009;4(3):e4940. doi: 10.1371/journal.pone.0004940. Epub 2009 Mar 31.

22.

Suppression of autoimmune diabetes by soluble galectin-1.

Perone MJ, Bertera S, Shufesky WJ, Divito SJ, Montecalvo A, Mathers AR, Larregina AT, Pang M, Seth N, Wucherpfennig KW, Trucco M, Baum LG, Morelli AE.

J Immunol. 2009 Mar 1;182(5):2641-53. doi: 10.4049/jimmunol.0800839.

23.

Daily topical tacrolimus therapy prevents skin rejection in a rodent hind limb allograft model.

Solari MG, Washington KM, Sacks JM, Hautz T, Unadkat JV, Horibe EK, Venkataramanan R, Larregina AT, Thomson AW, Lee WP.

Plast Reconstr Surg. 2009 Feb;123(2 Suppl):17S-25S. doi: 10.1097/PRS.0b013e318191bcbd.

PMID:
19182660
24.

Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses.

Mathers AR, Janelsins BM, Rubin JP, Tkacheva OA, Shufesky WJ, Watkins SC, Morelli AE, Larregina AT.

J Immunol. 2009 Jan 15;182(2):921-33.

25.

Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins.

Yasuoka H, Larregina AT, Yamaguchi Y, Feghali-Bostwick CA.

Open Rheumatol J. 2008;2:17-22. doi: 10.2174/1874312900802010017. Epub 2008 Mar 28.

26.

Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity.

Janelsins BM, Mathers AR, Tkacheva OA, Erdos G, Shufesky WJ, Morelli AE, Larregina AT.

Blood. 2009 Mar 26;113(13):3017-26. doi: 10.1182/blood-2008-06-163121. Epub 2008 Nov 5.

27.

Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition.

Montecalvo A, Shufesky WJ, Stolz DB, Sullivan MG, Wang Z, Divito SJ, Papworth GD, Watkins SC, Robbins PD, Larregina AT, Morelli AE.

J Immunol. 2008 Mar 1;180(5):3081-90.

28.

Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity.

Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P.

Cancer Res. 2007 Oct 15;67(20):10012-8.

29.

In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses.

Mathers AR, Tckacheva OA, Janelsins BM, Shufesky WJ, Morelli AE, Larregina AT.

J Immunol. 2007 Jun 1;178(11):7006-17.

30.

Professional antigen-presenting cells of the skin.

Mathers AR, Larregina AT.

Immunol Res. 2006;36(1-3):127-36. Review.

PMID:
17337773
31.

Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses in naive and activated T cells.

Perone MJ, Larregina AT, Shufesky WJ, Papworth GD, Sullivan ML, Zahorchak AF, Stolz DB, Baum LG, Watkins SC, Thomson AW, Morelli AE.

J Immunol. 2006 Jun 15;176(12):7207-20.

32.

Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells.

Wang Z, Larregina AT, Shufesky WJ, Perone MJ, Montecalvo A, Zahorchak AF, Thomson AW, Morelli AE.

Am J Transplant. 2006 Jun;6(6):1297-311.

33.

CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells.

Morelli AE, Rubin JP, Erdos G, Tkacheva OA, Mathers AR, Zahorchak AF, Thomson AW, Falo LD Jr, Larregina AT.

J Immunol. 2005 Dec 15;175(12):7905-15.

34.

Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.

Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr.

Cancer Res. 2005 Nov 1;65(21):10059-67.

35.

Changing paradigms in cutaneous immunology: adapting with dendritic cells.

Larregina AT, Falo LD Jr.

J Invest Dermatol. 2005 Jan;124(1):1-12. Review. No abstract available.

36.

Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells.

Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD, Zahorchak AF, Logar AJ, Wang Z, Watkins SC, Falo LD Jr, Thomson AW.

Blood. 2004 Nov 15;104(10):3257-66. Epub 2004 Jul 29.

PMID:
15284116
37.
38.

Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation.

Larregina AT, Morelli AE, Tkacheva O, Erdos G, Donahue C, Watkins SC, Thomson AW, Falo LD Jr.

Blood. 2004 Feb 1;103(3):811-9. Epub 2003 Oct 9.

PMID:
14551149
39.

Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production.

Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD Jr, Thomson AW.

Blood. 2003 Jan 15;101(2):611-20. Epub 2002 Sep 5.

PMID:
12393562
40.

Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS.

Zimmer MI, Larregina AT, Castillo CM, Capuano S 3rd, Falo LD Jr, Murphey-Corb M, Reinhart TA, Barratt-Boyes SM.

Blood. 2002 Apr 15;99(8):2859-68.

PMID:
11929776
41.

Dermal-resident CD14+ cells differentiate into Langerhans cells.

Larregina AT, Morelli AE, Spencer LA, Logar AJ, Watkins SC, Thomson AW, Falo LD Jr.

Nat Immunol. 2001 Dec;2(12):1151-8.

PMID:
11702065
42.

Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation.

Morelli AE, Zahorchak AF, Larregina AT, Colvin BL, Logar AJ, Takayama T, Falo LD, Thomson AW.

Blood. 2001 Sep 1;98(5):1512-23.

PMID:
11520802
43.

Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells.

Hackstein H, Morelli AE, Larregina AT, Ganster RW, Papworth GD, Logar AJ, Watkins SC, Falo LD, Thomson AW.

J Immunol. 2001 Jun 15;166(12):7053-62.

44.

Direct transfection and activation of human cutaneous dendritic cells.

Larregina AT, Watkins SC, Erdos G, Spencer LA, Storkus WJ, Beer Stolz D, Falo LD Jr.

Gene Ther. 2001 Apr;8(8):608-17.

45.
46.

Generating and regulating immune responses through cutaneous gene delivery.

Larregina AT, Falo LD Jr.

Hum Gene Ther. 2000 Nov 1;11(16):2301-5. Review.

PMID:
11084690
47.

Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway.

Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM, Takayama T, Logar AJ, Robbins PD, Falo LD, Thomson AW.

J Virol. 2000 Oct;74(20):9617-28.

48.

Adenoviruses encoding HPRT correct biochemical abnormalities of HPRT-deficient cells and allow their survival in negative selection medium.

Southgate TD, Bain D, Fairbanks LD, Morelli AE, Larregina AT, Simmonds HA, Castro MG, Löwenstein PR.

Metab Brain Dis. 1999 Dec;14(4):205-21.

PMID:
10850548
49.

Fas ligand-transfected myoblasts and islet cell transplantation.

Turvey SE, Gonzalez-Nicolini V, Kingsley CI, Larregina AT, Morris PJ, Castro MG, Lowenstein PR, Wood KJ.

Transplantation. 2000 May 15;69(9):1972-6.

PMID:
10830245
50.

Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.

Windeatt S, Southgate TD, Dewey RA, Bolognani F, Perone MJ, Larregina AT, Maleniak TC, Morris ID, Goya RG, Klatzmann D, Löwenstein PR, Castro MG.

J Clin Endocrinol Metab. 2000 Mar;85(3):1296-305.

PMID:
10720079

Supplemental Content

Loading ...
Support Center